Tactile Medical Appoints Dr. Thomas F. O’Donnell, Jr. as Chief Medical Officer

MINNEAPOLIS, July 11, 2017 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced the appointment of Thomas F. O’Donnell, Jr., MD, as Chief Medical Officer (CMO), effective June 19, 2017.

Dr. O’Donnell is the Senior Vascular Surgeon at Tufts Medical Center and the Benjamin Andrews Emeritus Professor and Chair of Surgery at Tufts University School of Medicine. He has served on the faculty of Tufts University School of Medicine for over 41 years and was the CEO and President of Tufts-New England Medical Center Hospitals, Inc. from 1996 through 2004. Dr. O’Donnell has also served as the President of the Society for Vascular Surgery, the American Venous Forum, the New England Society for Vascular Surgery, the Eastern Vascular Society and the Boston Surgical Society, and is currently on the editorial boards of The Journal of Vascular Surgery, Phlebology and WOUNDS. He has produced over 180 articles in peer-reviewed journals, 67 book chapters and 15 films on techniques primarily related to the subject of vascular disease. His career-long interest in venous and lymphatic disease was sparked by a post-surgical residency year in London at St. Thomas’ Hospital working under the late John Kinmonth and Sir Norman Browse, both seminal figures in the treatment of these vascular diseases.

Prior to his appointment as Chief Medical Officer, Dr. O’Donnell served as the chair of Tactile Medical’s Scientific Advisory Board (SAB) for four years.

“With his impressive career as a practicing surgeon, leading academic and accomplished executive at leading medical institutions, Dr. O’Donnell is an established thought leader in the field of vascular surgery,” said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. “Building on his four years as the chair of our Scientific Advisory Board, Tactile Medical welcomes Dr. O’Donnell to the senior leadership team, where he will be an invaluable resource as we continue to focus on developing advanced at-home therapies that provide relief to patients with chronic conditions.”

“I have enjoyed working with the Tactile Medical team and our SAB thought leaders,” said Dr. Thomas O’Donnell. “In this new position I am excited to have a greater involvement with current and future clinical trials with Tactile Medical devices, which we expect will help patients with the innovative treatment of lymphatic and venous disease.”

About Tactile Medical

Tactile Medical is a leader in developing and marketing at-home therapy devices that treat lymphedema and chronic venous insufficiency. Our unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical staff. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

Legal Notice Regarding Forward-Looking Statements:

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC, including the final prospectus for the Company’s initial public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners 443-213-0500 investorrelations@tactilemedical.com

Source:Tactile Systems Technology